Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish

Biogen's stock fell over 10% after its diranersen Alzheimer's drug missed the primary endpoint in the Phase 2 CELIA trial on May 14. However, the drug showed meaningful reductions in tau pathology and signs of slower clinical decline. Despite the setback, analysts remain bullish with a consensus price target of $215.62, citing the company's decision to advance the drug as a vote of confidence. Biogen's base business is supported by strong Leqembi sales growth (74% YoY to $168M) and the planned Apellis acquisition.

05/22/2026, 8:01 AM • Investing

ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

05/20/2026, 1:00 PM • GlobeNewswire

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

Biogen has historically outperformed the market over three decades, but faces current headwinds from biosimilar competition and weak revenue growth. While newer products like Leqembi (Alzheimer's) and high-dose Spinraza show promise with strong growth potential, the company's 2026 guidance projects declining sales. The stock carries heightened risk and is unlikely to deliver strong long-term returns without near-flawless execution.

04/16/2026, 5:30 AM • The Motley Fool

Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034

The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.

04/13/2026, 4:59 AM • GlobeNewswire

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.

04/01/2026, 1:00 PM • GlobeNewswire

Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump

Biogen reported Q4 2025 revenues of $2.28 billion, beating consensus estimates, driven by strong growth in Alzheimer's drug Leqembi with in-market sales up 54% to $134 million. The company's newer growth products offset declines in multiple sclerosis drugs. Biogen issued 2026 EPS guidance of $15.25-$16.25, above consensus, and the stock reached a new 52-week high, rising 4.28% to $193.29.

02/06/2026, 10:33 AM • Benzinga

Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

The U.S. Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first time the initiative includes drugs reimbursed under Medicare Part B. Negotiations will take place in 2026, with prices taking effect January 1, 2028. The second cycle negotiations are estimated to save Medicare $8.5 billion (36% reduction) if prices had been in place in 2024.

01/28/2026, 5:51 AM • Benzinga

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review

The FDA has accepted for Priority Review a supplemental application for LEQEMBI IQLIK, a subcutaneous autoinjector formulation of lecanemab for early Alzheimer's disease treatment. If approved by May 24, 2026, it would be the first anti-amyloid treatment offering at-home injection options for both treatment initiation and maintenance, potentially reducing healthcare resource requirements associated with intravenous dosing.

01/25/2026, 6:30 PM • GlobeNewswire

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

Tiziana Life Sciences is launching a Phase 2 clinical trial for intranasal foralumab to treat early Alzheimer's disease, targeting neuroinflammation in combination with existing anti-amyloid therapies like Leqembi.

12/12/2025, 2:10 PM • GlobeNewswire

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

Eisai and Biogen announced that LEQEMBI, an Alzheimer's treatment, has been added to China's Commercial Insurance Innovative Drug List, expanding access to early Alzheimer's disease treatment in the country.

12/08/2025, 6:30 PM • GlobeNewswire

Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot

Biogen and Eisai filed a new drug application in Japan for a subcutaneous formulation of Leqembi, seeking approval for a weekly at-home Alzheimer's treatment that could reduce healthcare resource requirements.

11/28/2025, 12:58 PM • Benzinga

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

Eisai has filed a new drug application in Japan for a subcutaneous autoinjector formulation of LEQEMBI (lecanemab), which could enable at-home weekly injections for early Alzheimer's disease treatment.

11/27/2025, 7:30 PM • GlobeNewswire

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Eisai and Biogen announced UK approval for LEQEMBI's maintenance dosing regimen for early Alzheimer's disease, allowing patients to transition to a less frequent IV treatment after 18 months of initial therapy.

11/13/2025, 6:30 PM • GlobeNewswire

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.

10/28/2025, 1:40 PM • Benzinga

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

Health Canada authorized LEQEMBI®, a new treatment for early Alzheimer's disease targeting amyloid-beta aggregates, which is the first approved treatment shown to reduce disease progression and slow cognitive decline.

10/26/2025, 7:30 PM • GlobeNewswire